Traditional fibroblast media utilise 10% serum combined with very simple basal media formulations.
The new CnT-PR-F medium uses an advanced basal medium formulation and a mix of defined growth factors to reduce the serum requirement down to 1%.
As a result, the new CnT-PR-F significantly increases isolation efficiency (50%) and growth rate (+40%), whilst reducing serum-associated variability.
Cells undergoing rapid proliferation are less responsive to differentiation and ECM-related triggers.
To obtain fully in-vivo like ECM production, we offer the new CnT-PR-ECM medium.
CnT-PR-ECM is fully defined, and delivers a 5x increase in ECM levels in response to vitamin C treatment compared with the proliferation medium CnT-PR-F.
Caltag Medsystems is the distributor of CellnTech products in the UK and Ireland. If you have any questions about these products, please contact us.